<DOC>
	<DOC>NCT00746447</DOC>
	<brief_summary>This study intends to study the efficacy and tolerability of once daily 3.0 g mesalazine granules vs. once daily 1.5 g mesalazine granules vs. three times daily 0.5 g mesalazine granules for maintenance of remission in patients with ulcerative colitis</brief_summary>
	<brief_title>Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Signed informed consent, Men or women aged 18 to 75 years, Historically confirmed diagnosis of ulcerative colitis by endoscopy and histology, Patient being in remission, defined (according to Rachmilewitz) as: Clinical Activity Index (CAI) &lt;= 4, and Endoscopic Index (EI) &lt; 4, Extent of inflammation during last acute episode was &gt;15 cm beyond the anal margin, Last acute episode ended within 3 months prior to study entry. Crohn's disease, Prior bowel resection leading to diarrhoea, Toxic megacolon, Gastric or duodenal ulcer, Haemorrhagic diathesis, Presence of symptomatic organic disease of the gastrointestinal tract (with the exception of haemorrhoids or hiatal hernia), Active colorectal cancer or a history of colorectal cancer, Serious other secondary illnesses of an acute or chronic nature, Asthma, Severe impairment of renal (e.g., serum creatinine &gt; 1.5 mg/dl) and/or liver functions (e.g., serum transaminase [ALT and/or AST] or alkaline phosphatase &gt;=2x upper limit of normal [ULN]), Application of immunosuppressants within 3 months and/or corticosteroids (oral, intravenous [IV] or topical rectal) within 30 days prior to baseline, Application of nonsteroidal antiinflammatory drugs (NSAIDs) as long term treatment (i.e. &gt; 6 weeks), other than acetylsalicylic acid (&lt;= 350 mg/day), or paracetamol, Known intolerance/hypersensitivity to salicylic acid and its derivatives or to any of the other constituents of the study drugs, Wellfounded doubt about the patient's cooperation, Existing or intended pregnancy, breastfeeding, Women of childbearing potential without adequate contraceptive protection, e.g., hormonal contraception, intrauterine device (IUD), doublebarrier method of contraception (e.g., use of a condom and spermicide), partner has undergone vasectomy and subject is in monogamous relationship. The investigator is responsible for determining whether the subject has adequate birth control for study participation, Participation in another clinical trial within the last 30 days,simultaneous participation in another clinical trial, or previous participation in this trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>maintenance</keyword>
	<keyword>5-ASA</keyword>
	<keyword>mesalamine</keyword>
	<keyword>mesalazine</keyword>
	<keyword>ulcerative colitis</keyword>
</DOC>